CD47-CAR-T cells
AssigneesProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd
InventorsLijun Wu, Vita Golubovskaya
Life of this patent
Estimating the term…
Abstract
The present invention provides a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against CD47, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. In one embodiment, the scFv is derived from a humanized anti-CD47 antibody. The present invention also provides T cells modified to express the CAR of the present invention.
Claims10
A chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus:
- (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein the scFv is against CD47,
- (ii) a transmembrane domain,
- (iii) a co-stimulatory domain, and
- (iv) an activating domain,
- wherein the scFv is derived from a humanized CD47 antibody and comprises the amino acid sequences of SEQ ID NOs:
- 11 and 12, linked by a linker.
Dependencies are inferred from the claim text.